Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial Authors and affiliations

150-word abstract 142 Main text 4,000-4,500 words (excluding abstract, excluding methods, references, and figure legends); ≤500-word introduction, short discussion 162-word introduction, 4364 words in main text overall Tables/figures 5-8 (main manuscript) 6 figures in main manuscript figures, 10 extended data figures References ≤60 (main text) 63 in main text, 4 in methods only Supplementary information Allowed 13 supplementary tables, 6 supplementary figures

[1]  B. Kerns,et al.  Cross-platform comparison of immune-related gene expression to assess intratumor immune responses following cancer immunotherapy. , 2021, Journal of immunological methods.

[2]  J. Galon,et al.  The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival , 2021, Cancers.

[3]  P. Van Loo,et al.  Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition , 2021, Cell.

[4]  J. Reis-Filho,et al.  Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy , 2020, Nature Cancer.

[5]  N. Ismaili,et al.  Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting. , 2020, Cancer treatment and research communications.

[6]  David J. Einstein,et al.  Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers. , 2020, Urology.

[7]  A. Ravaud,et al.  Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis , 2020, Journal for ImmunoTherapy of Cancer.

[8]  T. Powles,et al.  Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. , 2020, The Lancet. Oncology.

[9]  Craig B. Davis,et al.  Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. , 2020, The New England journal of medicine.

[10]  E. Schadt,et al.  Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing , 2020, Clinical Cancer Research.

[11]  Amber C. Donahue,et al.  Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial , 2020, Nature Medicine.

[12]  J. Galon,et al.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy , 2020, Nature Reviews Cancer.

[13]  J. Tabernero,et al.  Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Petljak,et al.  Molecular origins of APOBEC-associated mutations in cancer. , 2020, DNA repair.

[15]  S. Potluri,et al.  Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment. , 2020, Cell reports.

[16]  R. Madan,et al.  The immunotherapy revolution in genitourinary malignancies. , 2020, Immunotherapy.

[17]  M. Galsky,et al.  Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study. , 2020, Journal of Clinical Oncology.

[18]  P. Hegde,et al.  High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade , 2020, Nature Medicine.

[19]  A. Hartmann,et al.  Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy , 2020, Journal for immunotherapy of cancer.

[20]  B. Tran,et al.  Precision oncology in urothelial cancer , 2020, ESMO Open.

[21]  D. Largaespada,et al.  APOBEC3A catalyzes mutation and drives carcinogenesis in vivo , 2019, bioRxiv.

[22]  A. Ravaud,et al.  Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial , 2019, Nature Medicine.

[23]  J. Cogswell,et al.  Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin-Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform. , 2019, The Journal of molecular diagnostics : JMD.

[24]  Cees G. M. Snoek,et al.  Variable Selection , 2019, Model-Based Clustering and Classification for Data Science.

[25]  M. Rubin,et al.  Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling , 2019, Nature Communications.

[26]  Virginia Savova,et al.  Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. , 2019, Immunity.

[27]  P. Tamayo,et al.  APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy , 2018, Oncoimmunology.

[28]  L. Mariani,et al.  Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Ville Mustonen,et al.  The repertoire of mutational signatures in human cancer , 2018, Nature.

[30]  A. Gupta,et al.  Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab , 2018, Clinical Cancer Research.

[31]  James A. Eddy,et al.  The Immune Landscape of Cancer. , 2018, Immunity.

[32]  P. Hegde,et al.  Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.

[33]  M. Berger,et al.  Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Hideo Baba,et al.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.

[35]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[36]  Mark D. M. Leiserson,et al.  A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor , 2017, bioRxiv.

[37]  T. Powles,et al.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[38]  J. Meeks,et al.  APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response , 2017, bioRxiv.

[39]  T. Powles,et al.  A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. , 2017, Cancer treatment reviews.

[40]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[41]  M. Berger,et al.  DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma , 2017, Clinical Cancer Research.

[42]  G. Freeman,et al.  Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma , 2016, Scientific Reports.

[43]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[44]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[45]  J. Coleman,et al.  Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma , 2016, Current Urology Reports.

[46]  P. Bruhns,et al.  Mouse and human FcR effector functions , 2015, Immunological reviews.

[47]  K. Ballman,et al.  Biomarker: Predictive or Prognostic? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  B. Czerniak,et al.  Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. , 2015, Hematology/oncology clinics of North America.

[49]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[50]  M. Knowles,et al.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity , 2014, Nature Reviews Cancer.

[51]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[52]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[53]  V. Sondak,et al.  12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? , 2012, Scientific Reports.

[54]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[55]  J. Wesche,et al.  Roles of Fibroblast Growth Factor Receptors in Carcinogenesis , 2010, Molecular Cancer Research.

[56]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[57]  R. Gray.  Modeling Survival Data: Extending the Cox Model , 2002 .

[58]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  R. Prentice,et al.  Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study" , 1982 .

[60]  Shi-Yong Neo,et al.  The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.

[61]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[62]  Xianrang Song,et al.  Maturation of a central , 1996 .